Clonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx Only, Manufactured by: Actavis Laboratories UT Inc., Salt Lake City, UT 84108, Distributed by: Actavis Pharma, Inc, Parsippany, NJ, NDC 0591-3508-04 carton, NDC 0591-3508-54 pouch
Published April 15, 2026 · Recall initiated: March 19, 2026
Summary
FDA records drug Class II recall D-0472-2026, published April 15, 2026 and initiated March 19, 2026. Recalling firm: Teva Pharmaceuticals USA, Inc; Status: Ongoing; Reported quantity: 124,054 Cartons; Lot: Lot: 100060315, Exp.: 04/2026; 100068644, Exp.: 01/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
CGMP Deviations: use of an unapproved raw material
What to do
Voluntary: Firm initiated · Letter
Get an email if CLONIDINE TRANSDERMAL SYSTEM has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- CLONIDINE TRANSDERMAL SYSTEM
- Manufacturer
- Teva Pharmaceuticals USA, Inc
- Distributor
- Within U.S
- Lot
- Lot: 100060315, Exp.: 04/2026; 100068644, Exp.: 01/2027.
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAClonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, RxApril 15, 2026
- FDAClonidine Transdermal System, USP, 0.3 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, RxApril 15, 2026
- FDAGE Healthcare Omnipaque (iohexol) Injection, 350 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc.,April 15, 2026
- FDAGE Healthcare Omnipaque (iohexol) Injection, 300 mg/mL (64.7%), Rx Only, Distributed by: GE Healthcare Inc.,April 15, 2026
- FDAIsotretinoin Capsules, USP, 40 mg, 10 count Prescription Pacs, Rx only, Manufactured for: Teva PharmaceuticalsApril 15, 2026
- FDAClonidine Transdermal System, USP 0.1 mg/day, 4 patches per carton, Rx only, Manufactured by: ActavisNovember 24, 2021
Questions about this recall
Was Clonidine Transdermal System, USP, 0.1 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx Only, Manufactured by: Actavis Laboratories UT Inc., Salt Lake City, UT 84108, Distributed by: Actavis Pharma, Inc, Parsippany, NJ, NDC 0591-3508-04 carton, NDC 0591-3508-54 pouch recalled?
Yes. FDA published recall D-0472-2026 on April 15, 2026. Reported hazard: CGMP Deviations: use of an unapproved raw material
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: CLONIDINE TRANSDERMAL SYSTEM.